Page 126 - 2019_03-Haematologica-web

E. Brissot et al.
6. Duval M, Klein JP, He W, et al.
Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induc- tion failure. J Clin Oncol. 2010;28(23):3730- 3738.
7. Nagler A, Savani BN, Labopin M, et al. Outcomes after use of two standard ablative regimens in patients with refractory acute myeloid leukaemia: a retrospective, multi- centre, registry analysis. Lancet Haematol. 2015;2(9):e384-392.
8. Gyurkocza B, Lazarus HM, Giralt S. Allogeneic hematopoietic cell transplantation in patients with AML not achieving remis- sion: potentially curative therapy. Bone Marrow Transplant. 2017;52(8):1083-1090.
9. Dohner H, Weisdorf DJ, Bloomfield CD. acute myeloid leukemia. N Engl J Med. 2015;373(12):1136-1152.
10. Fung HC, Stein A, Slovak M, et al. A long- term follow-up report on allogeneic stem cell transplantation for patients with pri- mary refractory acute myelogenous leukemia: impact of cytogenetic characteris- tics on transplantation outcome. Biol Blood Marrow Transplant. 2003;9(12):766-771.
11. Michallet M, Thomas X, Vernant JP, et al. Long-term outcome after allogeneic hematopoietic stem cell transplantation for advanced stage acute myeloblastic leukemia: a retrospective study of 379 patients reported to the Societe Francaise de Greffe de Moelle (SFGM). Bone Marrow Transplant. 2000;26(11):1157-1163.
12. Wattad M, Weber D, Dohner K, et al. Impact of salvage regimens on response and overall survival in acute myeloid leukemia with induction failure. Leukemia. 2017;31(6):1306-1313.
13. Brissot E, Labopin M, Stelljes M, et al. Comparison of matched sibling donors ver- sus unrelated donors in allogeneic stem cell transplantation for primary refractory acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT. J Hematol Oncol. 2017;10(1):130.
14. Craddock C, Labopin M, Pillai S, et al. Factors predicting outcome after unrelated donor stem cell transplantation in primary refractory acute myeloid leukaemia. Leukemia. 2011;25(5):808-813.
15. Jabbour E, Daver N, Champlin R, et al. Allogeneic stem cell transplantation as initial salvage for patients with acute myeloid leukemia refractory to high-dose cytarabine- based induction chemotherapy. Am J Hematol. 2014;89(4):395-398.
16. Lee CJ, Savani BN, Mohty M, et al. Haploidentical hematopoietic cell transplan- tation for adult acute myeloid leukemia: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica. 2017;102 (11):1810-1822.
17. Passweg JR, Baldomero H, Bader P, et al. Use of haploidentical stem cell transplantation continues to increase: the 2015 European Society for Blood and Marrow Transplant activity survey report. Bone Marrow Transplant. 2017;52(6):811-817.
18. Bashey A, Zhang X, Sizemore CA, et al. T- cell-replete HLA-haploidentical hematopoi- etic transplantation for hematologic malig- nancies using post-transplantation
cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation. J Clin Oncol. 2013;31(10): 1310-1316.
19. Ciurea SO, Zhang MJ, Bacigalupo AA, et al. Haploidentical transplant with posttrans- plant cyclophosphamide vs matched unre- lated donor transplant for acute myeloid leukemia. Blood. 2015;126(8):1033-1040.
20. Bashey A, Zhang X, Jackson K, et al. Comparison of outcomes of hematopoietic cell transplants from T-replete haploidentical donors using post-transplantation cyclophosphamide with 10 of 10 HLA-A, -B, -C, -DRB1, and -DQB1 allele-matched unre- lated donors and HLA-identical sibling donors: a multivariable analysis including disease risk index. Biol Blood Marrow Transplant. 2016;22(1):125-133.
21. Rashidi A, DiPersio JF, Westervelt P, et al. Comparison of outcomes after peripheral blood haploidentical versus matched unre- lated donor allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia: a retrospective single- center review. Biol Blood Marrow Transplant. 2016;22(9):1696-1701.
22. Piemontese S, Ciceri F, Labopin M, et al. A comparison between allogeneic stem cell transplantation from unmanipulated hap- loidentical and unrelated donors in acute leukemia. J Hematol Oncol. 2017;10(1):24.
23. Versluis J, In 't Hout FE, Devillier R, et al. Comparative value of post-remission treat- ment in cytogenetically normal AML sub- classified by NPM1 and FLT3-ITD allelic ratio. Leukemia. 2017;31(1):26-33.
24. Grimwade D, Hills RK, Moorman AV, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010;116(3):354-365.
25. Bacigalupo A, Ballen K, Rizzo D, et al. Defining the intensity of conditioning regi- mens: working definitions. Biol Blood Marrow Transplant. 2009;15(12):1628-1633.
26. Schmid C, Schleuning M, Ledderose G, Tischer J, Kolb HJ. Sequential regimen of chemotherapy, reduced-intensity condition- ing for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfu- sion in high-risk acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol. 2005;23(24):5675-5687.
27. Malard F, Labopin M, Stuhler G, et al. Sequential intensified conditioning Regimen allogeneic hematopoietic stem cell trans- plantation in adult patients with intermedi- ate- or high-risk acute myeloid leukemia in complete remission: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2017;23(2):278-284.
28. Ringden O, Labopin M, Schmid C, et al. Sequential chemotherapy followed by reduced-intensity conditioning and allo- geneic haematopoietic stem cell transplanta- tion in adult patients with relapse or refrac- tory acute myeloid leukaemia: a survey from the Acute Leukaemia Working Party of
EBMT. Br J Haematol. 2017;176(3):431-439. 29. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A- matched sibling donors. Transplantation.
1974;18(4):295-304.
30. Terwey TH, Le Duc TM, Hemmati PG, et al.
NIH-defined graft-versus-host disease and evidence for a potent graft-versus-leukemia effect in patients with acute lymphoblastic leukemia. Ann Oncol. 2013;24(5):1363-1370.
31. Ruggeri A, Labopin M, Ciceri F, Mohty M, Nagler A. Definition of GvHD-free, relapse- free survival for registry-based studies: an ALWP-EBMT analysis on patients with AML in remission. Bone Marrow Transplant. 2016;51(4):610-611.
32. Clark TG, Altman DG, De Stavola BL. Quantification of the completeness of fol- low-up. Lancet. 2002;359(9314):1309-1310.
33. Wattad M, Weber D, Dohner K, et al. Impact of salvage regimens on response and overall survival in acute myeloid leukemia with induction failure. Leukemia. 2017;31 (6):1306-1313.
34. Raanani P, Dazzi F, Sohal J, et al. The rate and kinetics of molecular response to donor leucocyte transfusions in chronic myeloid leukaemia patients treated for relapse after allogeneic bone marrow transplantation. Br J Haematol. 1997;99(4):945-950.
35. Kanakry CG, Fuchs EJ, Luznik L. Modern approaches to HLA-haploidentical blood or marrow transplantation. Nat Rev Clin Oncol. 2016;13(2):132.
36. Byrd JC, Mrozek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002;100(13):4325-4336.
37. Grimwade D, Hills RK, Moorman AV, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010;116(3):354-365.
38. Tsirigotis P, Byrne M, Schmid C, et al. Relapse of AML after hematopoietic stem cell transplantation: methods of monitoring and preventive strategies. A review from the ALWP of the EBMT. Bone Marrow Transplant. 2016;51(11):1431-1438.
39. Stein EM, DiNardo CD, Pollyea DA, et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood. 2017;130(6):722-731.
40. Kayser S, Levis MJ, Schlenk RF. Midostaurin treatment in FLT3-mutated acute myeloid leukemia and systemic mastocytosis. Expert Rev Clin Pharmacol. 2017;10(11):1177-1189.
41. Antar A, Otrock ZK, El-Cheikh J, et al. Inhibition of FLT3 in AML: a focus on sorafenib. Bone Marrow Transplant. 2017;52 (3):344-351.
42. Konopleva M, Pollyea DA, Potluri J, et al. Efficacy and biological correlates of response in a phase II study of venetoclax monother- apy in patients with acute myelogenous leukemia. Cancer Discov. 2016;6(10):1106- 1117.
532
haematologica | 2019; 104(3)